bortezomib + carmustine + cyclophosphamide + dexamethasone + doxorubicin + melphalan + prednisone + vincristine

This is a multi-agent chemotherapy regimen composed of eight drugs—bortezomib, carmustine, cyclophosphamide, dexamethasone, doxorubicin, melphalan, prednisone, and vincristine. Each component has a distinct mechanism of action targeting malignant plasma cells or other rapidly dividing cells. Bortezomib is a proteasome inhibitor that disrupts protein degradation and induces apoptosis in cancer cells. Carmustine and melphalan are alkylating agents that cause DNA cross-linking and cell death. Cyclophosphamide is also an alkylating agent with immunosuppressive properties. Doxorubicin intercalates into DNA and inhibits topoisomerase II activity leading to cytotoxicity. Vincristine interferes with microtubule formation during mitosis. Dexamethasone and prednisone are corticosteroids that induce apoptosis in lymphoid malignancies and have anti-inflammatory effects. This combination represents an intensive chemotherapeutic approach for hematologic malignancies such as multiple myeloma or aggressive lymphomas when high tumor cytoreduction is required (e.g., prior to stem cell transplantation). While combinations of several of these agents (such as bortezomib with cyclophosphamide/dexamethasone or bortezomib with doxorubicin/cyclophosphamide/vincristine/prednisone) are well-established in clinical practice[1][5][9], the use of all eight together constitutes an aggressive regimen typically reserved for refractory cases or specific protocols.